baricitinib

Known as: 3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)- 
An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene… (More)
Is this relevant?
Highly Cited
2017
Highly Cited
2017
BACKGROUND Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2017
2017
OBJECTIVE We undertook this phase III study to evaluate baricitinib, an orally administered JAK-1/JAK-2 inhibitor, as monotherapy… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2017
Review
2017
Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with… (More)
  • table 1
  • figure 2
Is this relevant?
2016
2016
BACKGROUND Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a… (More)
Is this relevant?
2016
2016
OBJECTIVE To evaluate efficacy and safety, baricitinib [Janus kinase (JAK) 1/JAK2 inhibitor] was compared with placebo in… (More)
Is this relevant?
2015
2015
OBJECTIVES To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with… (More)
Is this relevant?
2015
2015
BACKGROUND Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?